European Journal of Rheumatology
Original Article

Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis

1.

University of Washington School of Medicine, Seattle, Washington, USA

2.

Department of Rheumatology, University of Washington School of Medicine, Seattle, Washington, USA

Eur J Rheumatol 2018; 5: 85-91
DOI: 10.5152/eurjrheum.2018.17113
Read: 189 Downloads: 34 Published: 03 September 2019

Abstract

 

Objective: Our study aims to determine whether the use of subcutaneous methotrexate (SC MTX) is associated with prolonged MTX use and lower incidence of hepatotoxicity in rheumatoid arthritis (RA) patients on MTX monotherapy and multiple drug therapy.

 

Methods: We conducted a retrospective cohort study using national databases of a large hospital system. Subjects had been diagnosed with RA and treated with MTX between September 30, 1999, and October 1, 2009. Outcomes of interest were the amount of time on MTX monotherapy or multiple disease-modifying anti-rheumatic drug (DMARD) therapy before addition of additional DMARDs or biologic agents, respectively. We conducted Cox regressions and Kaplan-Meier curves for association between SC MTX use and length of time before therapeutic change. We conducted chi-square tests for association between SC MTX use and elevated liver function tests (LFT).

 

Results: MTX monotherapy: SC MTX was associated with a significantly lower likelihood of therapeutic change (HR 0.64, 95% CI 0.52-0.78). Multiple DMARD therapy: SC MTX was not associated with a lower risk of adding a biologic (HR 1.13, 95% CI 0.97-1.31). Liver enzymes: There was no significant association between use of SC MTX and decreased frequency of abnormal LFTs [p=0.09 for alanine aminotransferase (ALT), p=0.924 for aspartate aminotransferase (AST)].

 

Conclusion: Use of SC MTX is associated with longer duration of MTX monotherapy before addition of other DMARDs/biologic agents in RA patients. Use of SC MTX is not associated with significantly longer duration of multiple DMARD therapy before addition of biologic agents. Use of oral MTX is not significantly associated with increased frequency of elevated LFTs.

 

Cite this article as: Harris E, Ng B. Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis. Eur J Rheumatol 2018; 5: 85-91.

Files
ISSN2147-9720 EISSN 2148-4279